Skip to content

Study on the efficacy and head MRI of precise localized repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression with headache symptoms

Study on the efficacy and head MRI of precise localized repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression with headache symptoms

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033228
Enrollment
Unknown
Registered
2020-05-25
Start date
2020-06-01
Completion date
Unknown
Last updated
2020-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

depression

Interventions

Drug Group:medication
rTMS Group:body surface localized transcranial magnetic stimulation therapy
Precise localized rTMS group:precise localized rTMS treatment

Sponsors

Department of Psychosomatic Medicine, the First Affiliated Hospital of Air Force Military Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. With the consent of the Ethics Committee of the First Affiliated Hospital of the Air Force Military Medical University, patients who have informed consent for the risk benefit of participating in the treatment of this project and signed a written informed consent; 2. Patients who meet the symptom criteria, severity criteria, course criteria, and exclusion criteria for the diagnosis of depression (international classification of diseases-10, ICD-10); 3. The Hamilton Depression Scale 17 (HAMD-17) score >= 18 points and the Pain Scale (VAS) score >= 1 point; 4. Aged 18-65 years; 5. Han nationality; 6. Right-handed; 7. Have not used antidepressants, antipsychotics or other psychotropic drugs in the past six months.

Exclusion criteria

Exclusion criteria: 1. Patients who suffering from other mental disorders that meet the diagnostic criteria of ICD-10; 2. Patients with severe physical diseases, such as epilepsy, liver and kidney function damage, diabetes, blood system diseases, etc.; 3. There are cardiovascular system diseases or abnormal ECG (including QTc >= 500 ms), or are taking drugs that may significantly affect the QT interval; 4. Narrow-angle glaucoma; 5. Those who have used ECT treatment six months before enrollment; 6. Those who have or have suffered from drug-induced malignant syndrome and severe delayed dyskinesia; 7. Those who have serious suicide attempts, or those who are seriously excited; 8. Those who cannot take the medicine as directed by the doctor, or who do not have a guardian; 9. Women who are pregnant or breastfeeding or plan to become pregnant; 10. Those with head trauma with consciousness disorder exceeding 5 minutes history; 11. Contraindications of magnetic resonance scanning (metal foreign bodies in the body, electronic devices, etc.); 12. Those with metal implants in the mouth, head, etc..

Design outcomes

Primary

MeasureTime frame
HAMD;VAS;

Secondary

MeasureTime frame
head MRI;

Countries

China

Contacts

Public ContactHuaning Wang

The First Affiliated Hospital of Air Force Military Medical University

13609161341@163.com+86 13609161341

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026